title: Analgesic and antiemetic needs following minimally invasive vs open staging for endometrial cancer.
abstract: OBJECTIVE
  We sought to assess perioperative outcomes of minimally invasive vs open endometrial cancer staging procedures.
  
  
  METHODS
  A total of 181 consecutive patients underwent open or minimally invasive hysterectomy with or without lymphadenectomy. Perioperative outcomes, analgesic, and antiemetic use were compared.
  
  
  RESULTS
  In all, 97 and 84 women underwent open and minimally invasive staging procedures, respectively. In the open staging group, median anesthesia time was shorter (197 vs 288 minutes; P < .0001), but recovery room stay (168 vs 140 minutes; P = .01) and hospital stay (4 vs 1 day; P < .0001) were longer. Median narcotic (13 vs 43 mg morphine equivalents; P < .0001) and antiemetic (43% vs 25%; P = .01) use were lower for minimally invasive surgery in the first 24 hours postoperatively. Median estimated blood loss was lower for minimally invasive procedures (100 vs 300 mL; P < .0001).
  
  
  CONCLUSIONS
  Minimally invasive staging for endometrial cancer is associated with lower use of narcotics and antiemetics, and shorter hospital stay compared to open procedures.
authors.affiliation: Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: Nicole D
authors.initials: ND
authors.lastname: Fleming
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Havrilesky
authors.forename: Fidel A
authors.initials: FA
authors.lastname: Valea
authors.forename: Terrence K
authors.initials: TK
authors.lastname: Allen
authors.forename: Gloria
authors.initials: G
authors.lastname: Broadwater
authors.forename: Amy
authors.initials: A
authors.lastname: Bland
authors.forename: Ashraf S
authors.initials: AS
authors.lastname: Habib
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D000932:Antiemetics / Q000008:administration & dosage*; D016063:Blood Loss, Surgical; D016889:Endometrial Neoplasms / Q000473:pathology* / Q000601:surgery; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000009:adverse effects / Q000379:methods*; D007902:Length of Stay; D008197:Lymph Node Excision / Q000009:adverse effects / Q000379:methods; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods*; D010149:Postoperative Pain / Q000188:drug therapy; D020250:Postoperative Nausea and Vomiting / Q000188:drug therapy; D012189:Retrospective Studies; D012371:Robotics / Q000379:methods; D013997:Time Factors
chemical_list: D000701:Analgesics, Opioid; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000932:Antiemetics